Skip to content

Randomized, open, positive parallel controlled study on the efficacy and safety of dimdazenil

Randomized, open, positive parallel controlled study on the efficacy and safety of dimdazenil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085915
Enrollment
Unknown
Registered
2024-06-21
Start date
2024-06-23
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary insomnia or emotional disorders accompanied by insomnia symptoms

Interventions

Dimdazenil group:Take medication at least 3 times a week
Midazolam group:Take medication at least 3 times a week

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Aged =18 and =65 years, of either gender; 2) A total sleep time of less than 6 hours accompanied by depressive episodes or bipolar disorder, or primary insomnia patients with a total sleep time of less than 6 hours; 3) Guarantee at least 7 hours of sleep time; 4) Have the behavioral capacity to read and complete scales and sleep diaries; 5) Voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1) Contraindications to Dimdazenil include allergies to any excipients of Dimdazenil, severe obstructive sleep apnea (OSA), respiratory dysfunction, or myasthenia gravis; 2) Contraindications to midazolam include allergies to any of its components, myasthenia gravis, severe cardiopulmonary dysfunction, severe liver dysfunction, or sleep apnea syndrome. 3) Patients exhibiting independent judgment, cognitive function, intellectual capacity, and behavioral abnormalities, which researchers have assessed as potentially influencing scale assessments and sleep diary completion; 4) According to the ICD-10 diagnostic criteria, the diagnosis is for other mental illnesses except for insomnia, depression, and bipolar disorder; 5) Individuals who currently have unstable physical illnesses or may compromise the safety of the trial, and are deemed unsuitable for participation by the researcher; 6) Women who are pregnant or breastfeeding; 7) Conditions that the researcher deems unsuitable for participation in this clinical study.

Design outcomes

Primary

MeasureTime frame
Subjectively recorded total sleep time;

Secondary

MeasureTime frame
Cognitive function assessment;Sleep efficiency;Sleep Awakening Time;Insomnia Severity Index;tired;Assessment of daytime attention and working memory function;Subjectively sleep latency;Somnolence;Sleep awakening frequency;EQ-5D-5L;

Countries

China

Contacts

Public ContactGang Wang

Beijing Anding Hospital Affiliated to Capital Medical University

anning.li@hotmail.com+86 139 1169 5727

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 9, 2026